Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

IMMUNIC, INC. Director's Dealing 2023

Jan 6, 2023

10196_dirs_2023-01-06_b7ef4645-fc23-430b-b171-0863be6a495c.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: IMMUNIC, INC. (IMUX)
CIK: 0001280776
Period of Report: 2023-01-02

Reporting Person: Whaley Glenn (Chief Financial Officer)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2023-01-02 Stock Option $1.40 A 110000 Acquired 2033-01-01 Common Stock (110000) Direct

Footnotes

F1: 25% of the shares underlying the option vest on the first anniversary of the grant date, with the remainder vesting in equal increments on each successive one-month anniversary thereafter for the next 36 months.